Dr Lahiru Handunnetthi
Lahiru Handunnetthi’s research interests are in the inflammatory diseases of the nervous system. His research focuses on understanding how human genetic variation contributes to neuropsychiatric disease and how knowledge of genetic risk factors can be used to identify novel drug targets.
He is involved in the functional characterisation of genetic risk alleles discovered through genome wide association studies and integration of various forms of genomic data to discover new drug targets.
Lahiru completed his DPhil at the Wellcome Centre for Genetics, University of Oxford. His work focused on understanding the interactions between genetic and environmental risk factors in multiple sclerosis. He studied medicine at the University of Cambridge and currently holds a NIHR funded Clinical Lectureship in Neurology. He is open to collaboration.
Key words: Neuroimmunology, Immunopsychiatry
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
Patone M. et al, (2021), Nat Med
Global proteomic analysis of extracellular matrix in mouse and human brain highlights relevance to cerebrovascular disease.
Pokhilko A. et al, (2021), J Cereb Blood Flow Metab, 41, 2423 - 2438
Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease.
Handunnetthi L. et al, (2021), Ann Neurol
Maternal infection in gestation increases the risk of non-affective psychosis in offspring: a meta-analysis.
Saatci D. et al, (2021), J Psychiatr Res, 139, 125 - 131
A genetics-led approach defines the drug target landscape of 30 immune-related traits
Fang H. et al, (2019), Nature Genetics, 51, 1082 - 1091